Biomarker Changes Associated With Both Dulaglutide and Cardiovascular Events in the REWIND Randomized Controlled Trial: A Nested Case-Control Post Hoc Analysis.

Gerstein HC, Lee SF, Paré G, Bethel MA, Colhoun HM, Hoover A, Lakshmanan M, Lin Y, Pirro V, Qian HR, Ruotolo G, Ryden L, Wilson JM, Duffin KL

Diabetes care1 May 2023Cited by 10 (Europe PMC)

PMID36897834DOI10.2337/dc22-2397PepBankPUB-36897834

Publisher page PubMedAsk about this study

Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanObservational studyMechanism
In REWIND participants, dulaglutide was associated with a greater reduction or smaller rise in NT-proBNP than placebo.
In plain wordsIn REWIND participants, dulaglutide was linked to lower NT-proBNP changes than placebo.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseNT-proBNP change
Study
n = 1,669
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · 2 yearsAs given in this study (human).
Source sentences
Summary
Compared with placebo, dulaglutide was associated with a greater reduction or lesser 2-year rise from baseline in N-terminal prohormone of brain natriuretic peptide (NT-proBNP), growth differentiation factor 15 (GDF-15), high-sensitivity C-reactive protein, and a greater 2-year rise in C-peptide.
1 context sentence(design, population, supporting numbers)
Summary · context
In this post hoc analysis, stored fasting baseline and 2-year plasma samples from 824 REWIND participants with MACE during follow-up and 845 matched non-MACE participants were analyzed for 2-year changes in 19 protein biomarkers. Two-year changes in 135 metabolites were also analyzed in 600 particip…
Report a problemFND-3689783401
02HumanObservational studyMechanism
In REWIND participants, dulaglutide was associated with a greater reduction or smaller rise in GDF-15 than placebo.
In plain wordsIn REWIND participants, dulaglutide was linked to lower GDF-15 changes than placebo.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseGDF-15 change
Study
n = 1,669
Comparator
Placebo
Outcome group
Inflammation markers · Metabolic and weight
Studied dose
Dose not stated · 2 yearsAs given in this study (human).
Source sentences
Summary
Compared with placebo, dulaglutide was associated with a greater reduction or lesser 2-year rise from baseline in N-terminal prohormone of brain natriuretic peptide (NT-proBNP), growth differentiation factor 15 (GDF-15), high-sensitivity C-reactive protein, and a greater 2-year rise in C-peptide.
1 context sentence(design, population, supporting numbers)
Summary · context
In this post hoc analysis, stored fasting baseline and 2-year plasma samples from 824 REWIND participants with MACE during follow-up and 845 matched non-MACE participants were analyzed for 2-year changes in 19 protein biomarkers. Two-year changes in 135 metabolites were also analyzed in 600 particip…
Report a problemFND-3689783402
03HumanObservational studyMechanism
In REWIND participants, dulaglutide was associated with a greater reduction or smaller rise in high-sensitivity C-reactive protein than placebo.
In plain wordsIn REWIND participants, dulaglutide was linked to lower C-reactive protein changes than placebo.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHigh-sensitivity C-reactive protein change
Study
n = 1,669
Comparator
Placebo
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated · 2 yearsAs given in this study (human).
Source sentences
Summary
Compared with placebo, dulaglutide was associated with a greater reduction or lesser 2-year rise from baseline in N-terminal prohormone of brain natriuretic peptide (NT-proBNP), growth differentiation factor 15 (GDF-15), high-sensitivity C-reactive protein, and a greater 2-year rise in C-peptide.
1 context sentence(design, population, supporting numbers)
Summary · context
In this post hoc analysis, stored fasting baseline and 2-year plasma samples from 824 REWIND participants with MACE during follow-up and 845 matched non-MACE participants were analyzed for 2-year changes in 19 protein biomarkers. Two-year changes in 135 metabolites were also analyzed in 600 particip…
Report a problemFND-3689783403
04HumanObservational studyMechanism
In REWIND participants, dulaglutide was associated with a greater rise in C-peptide than placebo.
In plain wordsIn REWIND participants, dulaglutide was linked to a greater C-peptide rise than placebo.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseC-peptide change
Study
n = 1,669
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 2 yearsAs given in this study (human).
Source sentences
Summary
Compared with placebo, dulaglutide was associated with a greater reduction or lesser 2-year rise from baseline in N-terminal prohormone of brain natriuretic peptide (NT-proBNP), growth differentiation factor 15 (GDF-15), high-sensitivity C-reactive protein, and a greater 2-year rise in C-peptide.
1 context sentence(design, population, supporting numbers)
Summary · context
In this post hoc analysis, stored fasting baseline and 2-year plasma samples from 824 REWIND participants with MACE during follow-up and 845 matched non-MACE participants were analyzed for 2-year changes in 19 protein biomarkers. Two-year changes in 135 metabolites were also analyzed in 600 particip…
Report a problemFND-3689783404
05HumanObservational studyMechanism
In REWIND participants, dulaglutide was associated with a greater fall in 2-hydroxybutyric acid than placebo.
In plain wordsIn REWIND participants, dulaglutide was linked to a greater fall in this metabolite than placebo.
Peptide
Dulaglutide (Trulicity)
Outcome
Decrease2-hydroxybutyric acid change
Study
n = 1,201
Comparator
Placebo
Outcome group
Metabolic pathways and metabolomics · Metabolic and weight
Studied dose
Dose not stated · 2 yearsAs given in this study (human).
Measurements
P value for 2-hydroxybutyric acid change vs placebo
< 0.001
dulaglutide vs placebo
Source sentences
Summary
Compared with placebo, dulaglutide was also associated with a greater fall from baseline in 2-hydroxybutyric acid and a greater rise in threonine (P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
In this post hoc analysis, stored fasting baseline and 2-year plasma samples from 824 REWIND participants with MACE during follow-up and 845 matched non-MACE participants were analyzed for 2-year changes in 19 protein biomarkers. Two-year changes in 135 metabolites were also analyzed in 600 particip…
Report a problemFND-3689783405
06HumanObservational studyMechanism
In REWIND participants, dulaglutide was associated with a greater rise in threonine than placebo.
In plain wordsIn REWIND participants, dulaglutide was linked to a greater threonine rise than placebo.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseThreonine change
Study
n = 1,201
Comparator
Placebo
Outcome group
Metabolic pathways and metabolomics · Metabolic and weight
Studied dose
Dose not stated · 2 yearsAs given in this study (human).
Measurements
P value for threonine change vs placebo
< 0.001
dulaglutide vs placebo
Source sentences
Summary
Compared with placebo, dulaglutide was also associated with a greater fall from baseline in 2-hydroxybutyric acid and a greater rise in threonine (P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
In this post hoc analysis, stored fasting baseline and 2-year plasma samples from 824 REWIND participants with MACE during follow-up and 845 matched non-MACE participants were analyzed for 2-year changes in 19 protein biomarkers. Two-year changes in 135 metabolites were also analyzed in 600 particip…
Report a problemFND-3689783406

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01394952

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Eli Lilly and Companyn = 9,90122 Jul 2011 to 21 Aug 2018

Cardiovascular Disease · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 8 Oct 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.